Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer

Annals of Oncology

Volumn 14, Issue 11, 2003, Pages 1623-1628

  Ganem, G ^a   Tubiana Hulin, M ^b   Fumoleau, P ^c   Combe, M ^d   Misset, J L ^e   Vannetzel, J M ^f   Bachelot, T ^g   De Ybarlucea, L R ^d   Lotz, V ^h   Bendahmane, B ^h   Dieras, V ⁱ  

^a CENTRE JEAN BERNARD   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d Hôpital Paul Brousse ^*

^e HÔPITAL PAUL BROUSSE   (France)

^f Clinique Hartmann   (France)

^g Centre Lyon Berard   (France)

^h SANOFI   (France)

ⁱ INSTITUT CURIE   (France)

Author keywords

Breast cancer; Docetaxel; Doxorubicin; Neoadjuvant chemotherapy

Indexed keywords

DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE;

ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDICAL DOCUMENTATION; NEUTROPENIA; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PREMEDICATION; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 10744227179     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg449     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-942.
2. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
3. Fischer B, Brown A, Mamounas, E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: finding from National Surgical Adjuvant Breast and Bowel project B-18. J Clin Oncol 1997; 15: 2483-2493.
4. Makris A, Powles TJ, Ashley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998; 9: 1179-1184.
5. Mauriac C, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicenter randomized trial. Ann Oncol 1999; 10: 47-52.
6. Fischer B, Saffer EA, Rudock C et al. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating-factor in mice. Cancer Res 1989; 49: 2002-2004.
7. Thames HD, Bucholtz TA, Smith CD. Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and locoregional treatment. J Clin Oncol 1999; 17: 2649-2658.
8. MacGrogan G, Mauriac L, Durand M et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB2, MiB1, pS2 and GSTπ. Br J Cancer. 1996; 74: 1458-1465.
9. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2-neu-2, p53 and BCL-2. Ann Oncol 2000; 11: 647-663.
10. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228.
11. Sataloff D, Mason B, Prestipino A et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180: 297-306.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
13. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17: 2341-2354.
14. Nabholtz JM, Thuerlimann B, Bezwoda WR et al. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Huntingt) 1997; 11 (8 Suppl 8): 25-30.
15. Bonneterre J, Roche H, Monnier A et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87: 1210-1215.
16. Sparano JA. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies. Semin Oncol 1998; 25 (Suppl 13): 10-15.
17. Nabholtz JM, Tonkin K, Smylie M et al. A review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Semin Oncol 1999; 26 (1 Suppl 3): 10-16.
18. Misset JL, Dieras V, Gruia G et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10: 553-560.
19. Kuerer HM, Sahin AA, Hunt KK et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999; 230: 72-78.
20. Ellis P, Smith I, Ashley S et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 1998; 16: 107-114.
21. Rouzier R, Extra JM, Klijanienko J et al. Incidence and prognostic significance of complete axillary down staging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20: 1304-1310.
22. Delgado GL, Nader LA, Brondi LG et al. Neoadjuvant (high-dose doxorubicin) plus adjuvant CMF chemotherapy for stages II and IIIA breast cancer: a phase II study. Proc Am Soc Clin Oncol 2000; 19: 133a (Abstr 521).
23. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: eight-years' experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
24. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
25. von Minckwitz G, Dan Costa S, Eiermann W et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17: 1999-2005.
26. Miller KD, McSkill-Stevens W, Sisk J et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17: 3033-3037.
27. Luporsi E, Vanlemmens L, Coudert B et al. 6 cycles of FEC 100 vs 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients: preliminary results of a randomized phase II trial of GIREC S01. Proc Am Soc Clin Oncol 2000; 10: 92a (Abstr 355).
28. Amat S, Bougnoux P, Penault-Llorga F et al. Primary chemotherapy for operable breast cancer: high pathological response rate induced by docetaxel. Proc Am Soc Clin Oncol 2000; 10: 128a (Abstr 500).
29. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from NSABP B-18. J Clin Oncol 1997; 15: 2479-2482.
30. van der Hage JA, van de Velde CJH, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19: 4224-4237.